Skip to main content
. Author manuscript; available in PMC: 2010 Mar 16.
Published in final edited form as: J Immunol. 2008 Aug 1;181(3):1692–1699. doi: 10.4049/jimmunol.181.3.1692

FIGURE 4.

FIGURE 4

CpG abrogates Treg suppression and allograft acceptance independent of IL-6. A, 2 × 105 CD4+CD25− T cells were cocultured in complete medium for 72 h in the presence or absence of CD4+CD25+ Tregs (2:1 ratio) and anti-CD3 plus anti-CD28-coated latex beads for 72 h. T cells were FACS sorted from either C57BL/6J or B6.IL-6−/− mice. Culture medium was supplemented with CpG DNA (3.3 µM) or left untreated. Tritiated thymidine was added to the cultures for the last 16 h of incubation. B, C57BL/6J (n = 24) and B6.IL-6−/− (n = 24) mice received bm12 (■, ●, ▲) or bm12.IL-6−/− skin grafts (□, ○, Δ), respectively, and received no treatment (■, □); treatment with anti-CD154 and rapamycin (●, ○); or treatment with anti-CD154, rapamycin, and CpG (▲, Δ), as previously described. Data are pooled from two experiments. *, p < 0.001 (circles vs triangles). p = NS between IL-6+/+ and IL-6−/− recipients within any treatment group (■ vs □; ●vs ○; ▲ vs Δ).